Barclays (LON:BARC) analyst Balaji Prasad maintained a Buy rating on Covetrus (NASDAQ:CVET) Inc on Friday, setting a price target of $46, which is approximately 53.33% above the present share price of $30.
Prasad expects Covetrus Inc to post earnings per share (EPS) of -$0.04 for the second quarter of 2021.
The current consensus among 5 TipRanks analysts is for a Moderate Buy rating of shares in Covetrus, with an average price target of $34.6.
The analysts price targets range from a high of $48 to a low of $20.
In its latest earnings report, released on 12/31/2020, the company reported a quarterly revenue of $1.12 billion and a net profit of -$19 million. The company's market cap is $4.09 billion.
According to TipRanks.com, Barclays analyst Balaji Prasad is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 8.4% and a 53.85% success rate.
Covetrus, Inc. engages in developing technologies and services for animal health industry. It also provides products, software, and services to help drive improved patient health, strong client relationships, and successful financial outcomes for veterinary professionals. The company was founded on April 13, 2018 and is headquartered in Melville, NY.